In the MSK MetTropism cohort, head and neck cancer and cervical cancer had the highest Nrf2-activating MUs frequency (6.07%), followed by cervical cancer (5.83%) and NSCLC (4.59%, Fig. 3B). Here, NFE2L2 is linked to head and neck cancer.